Antios Therapeutics Appoints Catherine Coffey Ross as VP, Medical Affairs
August 10, 2021 07:30 ET
|
Antios Therapeutics Inc.
ATLANTA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) today announced the appointment of Catherine Coffey Ross as Vice President, Medical Affairs. Ms. Coffey Ross’...
Antios Therapeutics’ ATI-2173 Demonstrates Potent Antiviral Activity and Evidence of Off-Treatment Sustained Viral Suppression in Chronic HBV Patients
June 23, 2021 07:30 ET
|
Antios Therapeutics Inc.
Data to be presented at the EASL Digital International Liver Congress™ 2021 Two poster presentations and supporting slides are available at...
Antios Therapeutics Announces Poster Presentation at the Inaugural HBV-TAG Conference
June 11, 2021 07:30 ET
|
Antios Therapeutics Inc.
HBV-TAG: Presentation of in vitro antiviral activity and Phase 1a healthy volunteer data demonstrating the safety, tolerability, and favorable pharmacokinetics of multiple ascending doses of ATI-2173 ...
Antios Therapeutics Continues Building Experienced Executive Team with Appointments of Katie Laessig, M.D., as SVP, Global Regulatory Affairs and Karen Fusaro as SVP, Clinical Operations
April 27, 2021 07:30 ET
|
Antios Therapeutics Inc.
Responsible for managing clinical development and the regulatory processes for ATI-2173, an ASPIN, which is in development as part of a potential curative regimen for chronic hepatitis B infection ...
Antios Therapeutics Doses First Patients in SAVE 1, a Phase 2a Study of ATI-2173 in Patients with Chronic Hepatitis B Virus (HBV)
April 21, 2021 07:30 ET
|
Antios Therapeutics Inc.
SAVE 1 to evaluate ATI-2173 in combination with tenofovir (TDF) vs. TDF plus placebo SAVE 1 to include cohort of Hepatitis Delta Virus (HDV) co-infected subjects to assess ATI-2173 activity against...
Antios Therapeutics Raises $96 Million in a Series B Financing
April 12, 2021 07:30 ET
|
Antios Therapeutics Inc.
Funding will support the Phase 2 clinical program of ATI-2173 in HBV Soleus Capital led the round with new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling...
Antios Therapeutics Appoints Accomplished Financial Executive, Tamra J. Adams, as its first Chief Financial Officer
February 17, 2021 07:30 ET
|
Antios Therapeutics Inc.
ATLANTA, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) today announced the appointment of seasoned financial executive, Tamra J. Adams, as the Company’s chief financial...
Antios Therapeutics Appoints Patrick T. Higgins to Board of Directors
February 11, 2021 07:30 ET
|
Antios Therapeutics Inc.
Former biopharmaceutical executive has been at the forefront of developing treatments for infectious diseases of the liver including HBV and HCV ATLANTA, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Antios...
Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection
January 25, 2021 07:30 ET
|
Antios Therapeutics Inc.
Study results expected to be presented in mid-2021 ATLANTA, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) today announced that it has completed the Phase 1b clinical trial...
Antios Therapeutics Appoints Gregory T. Mayes Chief Executive Officer
December 01, 2020 08:00 ET
|
Antios Therapeutics Inc.
Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead continued development of ATI-2173 as a potential backbone of a curative regimen...